This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pharma Clinical Trial Services: World Market 2013-2023

What prospects for leading regions and countries?

Developments worldwide will influence the market from 2013, especially improving clinical research in developing countries. There exist many opportunities for pharmaceutical companies and contract research providers. See outlooks for clinical testing.

You get individual forecasts to 2023 for 12 national markets and two regional groups, finding overall revenues:• US• Japan• Western Europe• Central and Eastern Europe (CEE)• Germany, France, UK, Italy and Spain (EU5)• Brazil, Russia, India and China (BRIC nations) and South Korea.

Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What affects clinical trial services from 2013?

Our report discusses issues and events affecting that industry and market from 2013:

• Future of outsourced phase I, II and III trials and post-marketing studies

• Demand from pharmaceutical and biopharma companies

• Regulatory policy

• Challenges in developed and developing countries

• Adaptive trial designs and focus on late-stage R&D pipeline candidates

• Patient recruitment and retention.

Also, we discuss these aspects of the field:• Social media as tools for engaging patients• Technological progress for more-efficient trials• Sharing of risk between the pharma industry and CROs• CRO consolidation, specialisation and globalisation• Studies on orphan diseases• Biomarkers in drug development.

See what the future holds. You investigate technological, economic and political matters, finding emphasis on companies, competition and business outlooks.

Leading companies and 2015 market value

We predict that the overall world market for clinical trial services will reach $30.6bn in 2015, and expand further to 2023. That outsourcing segment holds great potential for investment, development and revenue growth from 2013. You see how it will progress.

We review 15 leading companies, including these:• Quintiles• Covance• PPD• Parexel International• ICON• INC Research• inVentiv Health.

2 of 13

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs